Immunic advances MS therapy vidofludimus calcium during Q3 - ICYMI

Impact · against what's priced in

Immunic (IMUX) provides positive clinical data and patent extensions that increase the net present value of vidofludimus calcium. The combination of statistically significant disability improvement and extended exclusivity beyond 2041 serves as a material positive catalyst ahead of the 2026 Phase 3 data.

IMUX+0.70

No priced-in read yet

In context

The CALLIPER study's statistically significant effect on confirmed disability improvement and the extension of patent exclusivity beyond 2041 provide concrete value drivers and risk reduction for the asset.

Read from the article alone

• biotech
• healthcare
• IMUX
• clinical trials
• drug pipeline
• multiple sclerosis
• patents
• pharma
• phase 3

Search tags